Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05950607

Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0

The goal of this pragmatic cluster randomized clinical trial is to compare management of suspected infection in nursing home residents with dementia The main questions it aims to answer whether residents with dementia in nursing homes randomized to use a multicomponent intervention to optimize suspected infection management ( versus usual care) use less antibiotics and fewer burdensome interventions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

60 year–106 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hebrew SeniorLife

Boston, Massachusetts, 02131, United States

Location status: Recruiting

Location contact

Susan Mitchell

CONTACT

[email protected]

617-281-3669

About this study

This 52-month study (8 months preparation; 34 months trial conduct; 10 months data analyses and manuscript preparation)is a parallel cluster ePCT of an intervention to improve infection management for suspected infections among residents with moderate to advanced dementia (N=600; N=300/arm) living in NHs (N=50; N=25/arm). Facilities are members of a provider managed care network, Iowa Health Care Quality Network ('Network'). The intervention will be similar to the original TRAIN-AD program, but adapted for moderate to advanced dementia and rolled out in the Network. At each intervention NH, the intervention will be implemented for 24-months. Control NHs will employ usual care. In all NHs, there will be a 2-month startup period, 12-month resident enrollment period, and 24-months data collection period (Figure 2). Eligible residents with dementia will be identified using the EHR and Minimum DataSet (MDS) and followed up to 12 months. Outcome data will be ascertained from the EHR. Randomization and program roll out will be at the facility level. Analyses at the resident level. Clinical outcomes compared between arms at 12 months will be: 1. Antimicrobial courses/person-year in residents with moderate to advanced dementia (primary outcome) and all residents with dementia (secondary outcome) (Aim 1); and 2. Number of burdensome procedures/person-year used to manage suspected infections among residents with moderate to advanced dementia and those at all stages of dementia including: hospital transfers, urine specimens, chest x-rays, and blood cultures (secondary outcomes) (Aim 2). A process evaluation of implementation will be conducted in the intervention arm based on the RE-AIM framework1 (Aim 3) using quantitative and qualitative data (stakeholder interviews).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 60
  • A diagnosis of dementia (any type)
  • Cognitive Functional Scale (CFS) > 1
  • NH length of stay >90 days

The CFS score categorizes cognitive impairment status based on data in the electronic health record into: 1. None, 2. Mild, 3. Moderate, and 4. Severe (advanced). For the primary outcome, the analysis will be restricted to residents with a CFS score of 3 or 4.

Exclusion criteria

  • Less than 60 years of age
  • Living in nursing home for less than 90 days
  • Does not have diagnosis of dementia
  • Does not meet CFS >1 score

Treatment and study plan

TRAIN AD 2.0

Behavioral

The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, "Infection Management in Moderate to Advanced Dementia," C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. .

Primary outcomes

  1. Antimicrobial use in residents with moderate to advanced dementia

    Time frame: 12 months

    Number of antimicrobial courses/person-year among residents with moderate to advanced dementia.

Secondary outcomes

  1. Antimicrobial use in residents with dementia

    Time frame: 12 months

    Number of antimicrobial courses/person-year among residents with dementia at any stage.

  2. Burdensome interventions in residents with moderate to advanced dementia

    Time frame: 12 months

    Number of burdensome interventions (hospital transfers, bladder catheterization, chest x-ray, blood cultures) used to evaluate suspected infections/person-year among residents withmoderate to advanced dementia.

  3. Burdensome interventions in residents with dementia

    Time frame: 12 months

    Number of burdensome interventions (hospital transfers, bladder catheterization, chest x-ray, blood cultures) used to evaluate suspected infections/person-year among residents with dementia.

Study contacts

Contact information is provided by the study sponsor or research team.

Susan Mitchell, MD, MPH

CONTACT

[email protected]

16172813669

Sponsors and collaborators

Lead sponsor

Hebrew SeniorLife

Other

Collaborators

  • Brown University

Registry information

Official study title

Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0 (TRAIN-AD 2.0)

Acronym: TRAIN-AD 2

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jul 18, 2023
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.